These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 11692848)

  • 21. Antiviral treatment of HCV-related chronic hepatitis: is the cup half empty, or half full?
    Puoti C
    J Gastrointestin Liver Dis; 2007 Jun; 16(2):171-2. PubMed ID: 17592565
    [No Abstract]   [Full Text] [Related]  

  • 22. [Primer treatment of acute and chronic hepatitis C].
    Daruich J; Fainboim H; Frider B
    Acta Gastroenterol Latinoam; 2006 Jun; 36 Suppl 1():S52-6; discussion S74-82. PubMed ID: 16862862
    [No Abstract]   [Full Text] [Related]  

  • 23. HIV Infection, hepatitis C infection, and HAART: hard clinical choices.
    Kottilil S; Polis MA; Kovacs JA
    JAMA; 2004 Jul; 292(2):243-50. PubMed ID: 15249574
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug combination treats HIV and HCV.
    AIDS Patient Care STDS; 2004 Apr; 18(4):251. PubMed ID: 15142356
    [No Abstract]   [Full Text] [Related]  

  • 25. [Treatment of cirrhotics].
    Galdame O; Jorge A; Sordá J
    Acta Gastroenterol Latinoam; 2005 Jun; 35 Suppl 1():S42-5. PubMed ID: 20214300
    [No Abstract]   [Full Text] [Related]  

  • 26. Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients.
    Mira JA; López-Cortés LF; Merino D; Arizcorreta-Yarza A; Rivero A; Collado A; Ríos-Villegas MJ; González-Serrano M; Torres-Tortoso M; Macías J; Valera-Bestard B; Fernández-Fuertes E; Girón-González JA; Lozano F; Pineda JA;
    Antivir Ther; 2007; 12(8):1225-35. PubMed ID: 18240862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pegylated interferon alfa-2a. Improved prognosis in hepatitis C].
    MMW Fortschr Med; 2002 Sep; 144(38):59. PubMed ID: 12395712
    [No Abstract]   [Full Text] [Related]  

  • 28. Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus.
    Aguilar Marucco D; Veronese L; de Requena DG; Bonora S; Calcagno A; Cavecchia I; Sinicco A; De Rosa FG; Cariti G; Di Perri G
    J Antimicrob Chemother; 2007 Mar; 59(3):565-8. PubMed ID: 17213263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ribavirin in combination therapy for HCV chronic infection in HIV patients: how to win the war after winning the first battle?
    Souvignet C; Maynard M; Gagnieu MC; Trepo C
    J Hepatol; 2007 Jul; 47(1):1-3. PubMed ID: 17509722
    [No Abstract]   [Full Text] [Related]  

  • 30. Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study.
    Tural C; Solà R; Rubio R; Santín M; Planas R; Quereda C; Berenguer J; Montes-Ramírez M; Clotet B;
    J Viral Hepat; 2007 Oct; 14(10):704-13. PubMed ID: 17875005
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Chronic hepatitis C viral infection with persistent normal serum alanine aminotransferases].
    Huang CX; Bai XF
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jan; 13(1):70-1. PubMed ID: 15670508
    [No Abstract]   [Full Text] [Related]  

  • 32. [Chronic hepatitis C. First treatment].
    Colombato L; Descalzi V; Gadano A
    Acta Gastroenterol Latinoam; 2005 Jun; 35 Suppl 1():S37-9. PubMed ID: 20214297
    [No Abstract]   [Full Text] [Related]  

  • 33. PEG-IFN, RBV dosing during chronic HCV re-treatment.
    Highleyman L
    IAPAC Mon; 2007 Feb; 13(2):55. PubMed ID: 17948601
    [No Abstract]   [Full Text] [Related]  

  • 34. Mitochondrial effects of a 24-week course of pegylated-interferon plus ribavirin in asymptomatic HCV/HIV co-infected patients on long-term treatment with didanosine, stavudine or both.
    Ballesteros AL; Miró O; López S; Fuster D; Videla S; Martínez E; Garrabou G; Salas A; Côté H; Tor J; Rey-Joly C; Planas R; Clotet B; Tural C
    Antivir Ther; 2004 Dec; 9(6):969-77. PubMed ID: 15651755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjects.
    Behler CM; Vittinghoff E; Lin F; Chung RT; Peters MG; Robbins GK; Volberding PA
    Clin Infect Dis; 2007 May; 44(10):1375-83. PubMed ID: 17443478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treating HCV infection in HIV/HCV-coinfected patients.
    Boyle B
    IAPAC Mon; 2004 Jan; 10(1):34-9. PubMed ID: 15108673
    [No Abstract]   [Full Text] [Related]  

  • 37. T cell receptor excision circles (TRECs), CD4+, CD8+, and their CD45RO+, and CD45RA+, subpopulations in hepatitis C virus (HCV)-HIV-co-infected patients during treatment with interferon alpha plus ribavirin: analysis in a population on effective antiretroviral therapy.
    Arizcorreta A; Márquez M; Fernández-Gutiérrez C; Guzmán EP; Brun F; Rodríguez-Iglesias M; Girón-González JA
    Clin Exp Immunol; 2006 Nov; 146(2):270-7. PubMed ID: 17034579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin.
    Núñez M; Ocampo A; Aguirrebengoa K; Cervantes M; Pascual A; Echeverria S; Asensi V; Barreiro P; Garcia-Samaniego J; Soriano V;
    J Viral Hepat; 2008 May; 15(5):363-9. PubMed ID: 18179454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment of relapsers].
    Galdame O; Manero E; Reggiardo V
    Acta Gastroenterol Latinoam; 2005 Jun; 35 Suppl 1():S39-41. PubMed ID: 20214298
    [No Abstract]   [Full Text] [Related]  

  • 40. [Coinfection with HIV and HCV--epidemiologic, diagnostic, clinical and therapeutic implications].
    Jabłonowska E
    Przegl Epidemiol; 2004; 58(4):621-8. PubMed ID: 15810503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.